Allogene reports 67% ORR and 58% CR in Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in r/r LBCL

Allogene Therapeutics, Inc.

67% ORR and 58% CR in CAR T-naive r/r LBCL patients (n=12) treated with Phase 2 regimen at ASCO.
5 of 7 complete responders maintained CR at 6 months; median DOR 23.1 months; 3 patients in remission >24 months, longest >31 months.
No Grade 3+ CRS, ICANS, or GvHD; cytopenias and infections manageable; safety comparable to autologous CAR T.
Pivotal Phase 2 ALPHA2 trial of ALLO-501A enrolling; expected enrollment completion in first half of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.